ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study

被引：3

作者：

Moscetti, Luca ^{[1
,7
]}

Mentuccia, Lucia ^{[2
]}

Vici, Patrizia ^{[3
]}

Quadrini, Silvia ^{[2
]}

Sperduti, Isabella ^{[4
]}

Pizzuti, Laura ^{[3
]}

Fabbri, Maria Agnese ^{[1
]}

Vaccaro, Angela ^{[2
]}

Sacca, Marcello Maugeri ^{[3
,6
]}

Barba, Maddalena ^{[3
,6
]}

Sergi, Domenico ^{[3
]}

Zampa, Germano ^{[5
]}

Gamucci, Teresa ^{[2
]}

机构：

[1] Belcolle Hosp, AUSL Viterbo, Div Med Oncol, Viterbo, Italy

[2] ASL Frosinone, Med Oncol Unit, Frosinone, Italy

[3] Regina Elena Inst Canc Res, Div Med Oncol B, Rome, Italy

[4] Regina Elena Inst Canc Res, Biostat, Rome, Italy

[5] Nuovo Regina Margherita Hosp, Med Oncol Unit, Rome, Italy

[6] Regina Elena Inst Canc Res, Sci Direct, Rome, Italy

[7] Azienda Osped Univ Policlin Modena, Dept Oncol & Hematol, Modena, Italy

来源：

FUTURE ONCOLOGY | 2017年 / 13卷 / 17期

关键词：

Edmonton symptoms assessment scale; eribulin mesylate; metastatic breast cancer; quality of life; QUALITY-OF-LIFE; CAPECITABINE; MESYLATE; SCALE;

D O I：

10.2217/fon-2017-0062

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations. Patients & methods: A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires. Results: A significant ESAS score improvement was observed with a 10% median decrease. No differences were revealed for the QoL scores. Conclusion: The analysis of ESAS and Functional Assessment of Cancer Therapy scores showed that eribulin mesylate contributes to preserve QoL in MBC patients.

引用

页码：1517 / 1525

页数：9

共 16 条

[1] The Missing Voice of Patients in Drug-Safety Reporting [J].

Basch, Ethan .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (10) :865-869

[2] Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument [J].

Brady, MJ ;

Cella, DF ;

Mo, F ;

Bonomi, AE ;

Tulsky, DS ;

Lloyd, SR ;

Deasy, S ;

Cobleigh, M ;

Shiomoto, G .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :974-986

[3]

Bruera E, 1991, J Palliat Care, V7, P6

[4] 1st International consensus guidelines for advanced breast cancer (ABC 1) [J].

Cardoso, F. ;

Costa, A. ;

Norton, L. ;

Cameron, D. ;

Cufer, T. ;

Fallowfield, L. ;

Francis, P. ;

Gligorov, J. ;

Kyriakides, S. ;

Lin, N. ;

Pagani, O. ;

Senkus, E. ;

Thomssen, C. ;

Aapro, M. ;

Bergh, J. ;

Di Leo, A. ;

El Saghir, N. ;

Ganz, P. A. ;

Gelmon, K. ;

Goldhirsch, A. ;

Harbeck, N. ;

Houssami, N. ;

Hudis, C. ;

Kaufman, B. ;

Leadbeater, M. ;

Mayer, M. ;

Rodger, A. ;

Rugo, H. ;

Sacchini, V. ;

Sledge, G. ;

van't Veer, L. ;

Viale, G. ;

Krop, I. ;

Winer, E. .

BREAST, 2012, 21 (03) :242-252

[5] Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial [J].

Cortes, Javier ;

Hudgens, Stacie ;

Twelves, Chris ;

Perez, Edith A. ;

Awada, Ahmad ;

Yelle, Louise ;

McCutcheon, Susan ;

Kaufman, Peter A. ;

Forsythe, Anna ;

Velikova, Galina .

BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (03) :509-520

[6] Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study [J].

Cortes, Javier ;

O'Shaughnessy, Joyce ;

Loesch, David ;

Blum, Joanne L. ;

Vahdat, Linda T. ;

Petrakova, Katarina ;

Chollet, Philippe ;

Manikas, Alexey ;

Dieras, Veronique ;

Delozier, Thierry ;

Vladimirov, Vladimir ;

Cardoso, Fatima ;

Koh, Han ;

Bougnoux, Philippe ;

Dutcus, Corina E. ;

Seegobin, Seth ;

Mir, Denis ;

Meneses, Nicole ;

Wanders, Jantien ;

Twelves, Chris .

LANCET, 2011, 377 (9769) :914-923

[7] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[8] A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale [J].

Eton, DT ;

Cella, D ;

Yost, KJ ;

Yount, SE ;

Peterman, AH ;

Neuberg, DS ;

Sledge, GW ;

Wood, WC .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (09) :898-910

[9] Assessing the Quality and Value of Quality-of-Life Measurement in Breast Cancer Clinical Trials [J].

Ganz, Patricia A. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (03) :196-199

[10] Health-related quality-of-life measurement in randomized clinical trials in breast cancer - Taking stock [J].

Goodwin, PJ ;

Black, JT ;

Bordeleau, LJ ;

Ganz, PA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (04) :263-281

← 1 2 →